Novel biomarkers for the differential diagnosis of paediatric MYH9 ‐related diseases and immune thrombocytopenia revealed by plasma proteomics
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70720 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Xiaojuan Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Proteomics, Myosin Heavy Chains, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Shenzhen Science and Technology Innovation Program.
Abstract (Originalsprache)
Differentiating myosin heavy chain 9 (MYH9)‐related disease (MYH9‐RD) from immune thrombocytopenia (ITP) remains clinically challenging. This study utilized data‐independent acquisition (DIA) plasma proteomics to identify distinguishing biomarker signatures. Profiling cohorts of MYH9‐RD ( n = 10), ITP ( n = 10) and healthy controls ( n = 14) quantified 2533 proteins, revealing distinct immune and metabolic remodelling. We identified 91 MYH9‐RD‐specific and 124 ITP‐specific proteins, highlighting divergent organ involvement pathways. By integrating protein–protein interaction networks with Boruta and Random Forest machine‐learning algorithms, we identified preliminary candidate biomarker panels (MYH9‐RD panel: von Willebrand factor [VWF], cholesteryl ester transfer protein [CETP], apolipoprotein A‐1 [APOA1], periostin [POSTN]; ITP panel: neutrophil gelatinase‐associated lipocalin [NGAL], plasminogen activator inhibitor‐1 [PAI‐1], carboxypeptidase B2 [CPB2]) that demonstrated excellent apparent discrimination. This exploratory study provides a hypothesis‐generating framework, revealing fundamentally distinct molecular landscapes between congenital and acquired macrothrombocytopenia. Pending rigorous future external validation, these preliminary candidate biomarkers offer novel biological insights into the divergent pathophysiologies of MYH9‐RD and ITP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
- Department of Laboratory Medicine, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
- Laboratory of General Surgery, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Ruizhi Wang, Weigen Wu, Xiaoying Fu, Meifang He
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Luo, X., Cao, K., Wang, R., Wu, W., Huang, T., Zhang, Y., Fu, X., Li, D., & He, M. (2026). Novel biomarkers for the differential diagnosis of paediatric MYH9 ‐related diseases and immune thrombocytopenia revealed by plasma proteomics. British Journal of Haematology. https://doi.org/10.1111/bjh.70720
Vancouver
Luo X, Cao K, Wang R, Wu W, Huang T, Zhang Y, et al. Novel biomarkers for the differential diagnosis of paediatric MYH9 ‐related diseases and immune thrombocytopenia revealed by plasma proteomics. British Journal of Haematology. 2026. doi:10.1111/bjh.70720
BibTeX
@article{Luo2026,
author = {Luo, Xiaojuan and Cao, Ke and Wang, Ruizhi and Wu, Weigen and Huang, Tao and Zhang, Yan and Fu, Xiaoying and Li, Defa and He, Meifang},
title = {Novel biomarkers for the differential diagnosis of paediatric MYH9 ‐related diseases and immune thrombocytopenia revealed by plasma proteomics},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70720}
}
EUVIMED